FindTrial
Sign In

Comparison of Brihatyadi Kashaya and Trinapanchamoola Kashaya for relief of symptoms in lower urinary tract infection.

An open label double arm randomized an clinical study to compare the effect of brihatyadi kashaya and trinapanchamoola kwatha in the management of garbhini mutrakrichra w.s.r to lower urinary tract infection - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105262
Enrollment
40
Registered
2026-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O234- Unspecified infection of urinary tract in pregnancy Health Condition 2: O234- Unspecified infection of urinary tract in pregnancy

Interventions

None listed

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Garbhini between the age group of 18 38 years with lakshanas of garbhini mutrakrichra and urinary tract infection as per diagnostic criteria Both primi and multi gravida Patients in all three trimesters

Exclusion criteria

Exclusion criteria: oPatients suffering from any systemic disorders which interfere with the course of treatment. oThe patient having surgical history of urinary tract and its complications

Design outcomes

Primary

MeasureTime frame
To assess and compare the reduction in clinical symptoms of Garbhini Mutrakrichra dysuria burning micturition frequency urgency nocturia and improvement in urine routine microscopy reduction in pus cells following treatment with Brihatyadi Kashaya and Trinapanchamoola KwathaTimepoint: 1 Year 1 Month—

Secondary

MeasureTime frame
nilTimepoint: not applicable—

Countries

India

Contacts

Public ContactDr Papiya Jana

Sri Kalabyrabyraveshwaraswamy Ayurvedic Medical College Hospital and research centre

drpapiya@gmail.com9886716216

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026